Daiichi Sankyo (OTCMKTS:DSNKY) Stock Price Breaks Below 50 Day Moving Average – Here’s What Happened

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) passed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $17.80 and traded as low as $17.5940. Daiichi Sankyo shares last traded at $17.68, with a volume of 74,227 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Performance

The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The company has a market cap of $32.94 billion, a PE ratio of 18.04, a P/E/G ratio of 2.08 and a beta of -0.10. The business’s fifty day moving average is $17.80 and its 200-day moving average is $17.57.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its earnings results on Friday, October 30th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.08. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. The business had revenue of $3.77 billion during the quarter, compared to analysts’ expectations of $3.58 billion. As a group, research analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 EPS for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).